Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease - PubMed (original) (raw)
Clinical Trial
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
M Arora et al. Biol Blood Marrow Transplant. 2001.
Free article
Abstract
Chronic graft-versus-host disease (CGVHD) is a major cause of morbidity following allogeneic bone marrow transplantation. Thalidomide is active in salvage therapy for high-risk or resistant CGVHD. In a prospective randomized trial, we tested initial therapy with thalidomide. Patients with extensive CGVHD were randomized to receive either cyclosporine and alternate-day prednisone (n = 27, no-thalidomide [no-thal] group) or cyclosporine, prednisone, and thalidomide (200-800 mg/day; n = 27, thal group). Although most patients responded, initial therapy with thalidomide did not improve control of CGVHD. Response rates were 83% versus 89% at 2 months (P = .7), 88% versus 84% at 6 months (P > .8) and 85% versus 73% at 1 year (P = .5) in the thal and no-thal groups, respectively. Multivariate analysis revealed related donor transplant (odds ratio [OR] = 11.3; P =.03) and de novo or quiescent onset of CGVHD (OR = 7.7; P =.04) to be significant predictors of good early response, whereas a platelet count of > or =100,000/microL was a significant predictor of good response (OR = 10.4; P =.04) at 1 year. Survival for the thal and no-thal groups was similar at 1 year (66% versus 74%) and 2 years (66% versus 54%, P = .85). Multivariate analysis revealed progressive onset CGVHD (relative risk [RR] = 4.2; P =.01), unrelated donor (RR = 5.7; P < .01), sex mismatch (RR = 7.9; P < .01), and platelet counts of <100,000/microL (RR = 3.8; P = .01) as significant predictors of poorer survival. These data suggest that despite a high response rate (79% response and 53% complete response) and encouraging survival rates (70% at 1 year and 60% at 2 years), thalidomide offers no clinical benefit when incorporated into initial therapy for CGVHD. The value of thalidomide as salvage therapy requires further study.
Similar articles
- Thalidomide for treatment of patients with chronic graft-versus-host disease.
Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Koc S, et al. Blood. 2000 Dec 1;96(12):3995-6. Blood. 2000. PMID: 11090092 Clinical Trial. - Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Kumar S, et al. Bone Marrow Transplant. 2001 Jun;27(11):1133-40. doi: 10.1038/sj.bmt.1703053. Bone Marrow Transplant. 2001. PMID: 11551023 - Thalidomide as salvage therapy for chronic graft-versus-host disease.
Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ. Parker PM, et al. Blood. 1995 Nov 1;86(9):3604-9. Blood. 1995. PMID: 7579470 Clinical Trial. - Chronic graft-versus-host disease: Pathogenesis and clinical management.
Pérez-Simón JA, Sánchez-Abarca I, Díez-Campelo M, Caballero D, San Miguel J. Pérez-Simón JA, et al. Drugs. 2006;66(8):1041-57. doi: 10.2165/00003495-200666080-00002. Drugs. 2006. PMID: 16789791 Review. - Thalidomide for treatment of graft-versus-host disease.
Vogelsang GB, Hess AD, Santos GW. Vogelsang GB, et al. Bone Marrow Transplant. 1988 Sep;3(5):393-8. Bone Marrow Transplant. 1988. PMID: 3056547 Review.
Cited by
- Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease.
Gavriilaki E, Papchianou E, Karavalakis G, Batsis I, Panteliadou A, Lazaridou A, Mallouri D, Constantinou V, Karvouni P, Evangelidis P, Papakonstantinou A, Papalexandri A, Kaloyannidis P, Spyridis N, Bousiou Z, Vardi A, Yannaki E, Sotiropoulos D, Sakellari I. Gavriilaki E, et al. Pharmaceuticals (Basel). 2024 Sep 27;17(10):1279. doi: 10.3390/ph17101279. Pharmaceuticals (Basel). 2024. PMID: 39458920 Free PMC article. - Chronic graft-versus-host disease: unresolved complication or ancient history?
Pidala JA, Gooley TA, Luznik L, Blazar BR. Pidala JA, et al. Blood. 2024 Sep 26;144(13):1363-1373. doi: 10.1182/blood.2023022735. Blood. 2024. PMID: 39008818 Review. - The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Maurer K, Soiffer RJ. Maurer K, et al. Expert Rev Hematol. 2023 Jul-Dec;16(12):943-962. doi: 10.1080/17474086.2023.2273847. Epub 2023 Dec 18. Expert Rev Hematol. 2023. PMID: 37906445 Free PMC article. Review. - Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, Yakoub-Agha I, Ko BS, Bruno B, Waller EK, Yared J, Sohn SK, Bulabois CE, Teshima T, Jacobsohn D, Greinix H, Mokatrin A, Lee Y, Wahlstrom JT, Styles L, Socie G. Miklos DB, et al. J Clin Oncol. 2023 Apr 1;41(10):1876-1887. doi: 10.1200/JCO.22.00509. Epub 2023 Jan 6. J Clin Oncol. 2023. PMID: 36608310 Free PMC article. Clinical Trial. - Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Baumrin E, et al. J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23. J Am Acad Dermatol. 2024. PMID: 36572064 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical